Research shows potential of microneedles to target therapeutics to the back of the eye
Researcher Samirkumar Patel displays a prototype microneedle used to inject therapeutics into specific locations in the eye. The technology could allow doctors to target drugs to locations in the eye that are now difficult to reach. Credit: Georgia Tech Photo: Gary Meek
Thanks to tiny microneedles, eye doctors may soon have a better way to treat diseases such as macular degeneration that affect tissues in the back of the eye. That could be important as the population ages and develops more eye-related illnesses and as pharmaceutical companies develop new drugs that otherwise could only be administered by injecting into the eye with a hypodermic needle.
For the first time, researchers from the Georgia Institute of Technology and Emory University have demonstrated that microneedles less than a millimeter in length can deliver drug molecules and particles to the eye in an animal model. The injection targeted the suprachoroidal space of the eye, which provides a natural passageway for drug injected across the white part (sclera) of the eye to flow along the eye's inner surface and subsequently into the back of the eye. The minimally-invasive technique could represent a significant improvement over conventional methods that inject drugs into the center of the eye or use eyedrops, which have limited effectiveness in treating many diseases.
The study was reported in the July issue of the journal Investigative Ophthalmology & Visual Science. The research was supported by the National Eye Institute, which is part of the National Institutes of Health, and by the organization Research to Prevent Blindness.
"This research could lead to a simple and safe procedure that offers doctors a better way to target drugs to specific locations in the eye," said Samirkumar Patel, the paper's first author and a postdoctoral researcher at Georgia Tech when the research was conducted. "The design and simplicity of the microneedle device may make it more likely to be used in the clinic as a way to administer drug formulations into the suprachoroidal space that surrounds the eye."
Patel, who is now director of research for Clearside Biomedical a startup company formed to commercialize the technology said the study also showed that the suprachoroidal space could accommodate a variety of drugs and microparticles. That could open the door for the use of timed-release drugs that could reduce the need for frequent injections to treat chronic eye diseases.
Researcher Samirkumar Patel displays a prototype microneedle used to inject therapeutics into specific locations in the eye. The image behind him on the screen is a magnified view of a site where fluorescent particles were injected into the suprachoroidal space using a microneedle. Credit: Georgia Tech Photo: Gary MeekThe suprachoroidal space is located between two important structures in the eye: the sclera and the choroid. Fluids injected into that space travel circumferentially around the eye, which flows drug solution directly over the choroid and adjacent retina which are the targets for many drug compounds. The new study showed that injections of fluids containing molecules and particles into that space not only reach the targeted structures, but also remain there for extended time periods. And equally important, the molecules and particles do not significantly reach the lens or front part of the eye, where side effects from drugs can occur.
"The study showed that if we inject non-degradable particles into the suprachoroidal space and wait as long as two months, the particles remain," said Mark Prausnitz, a Regents professor in Georgia Tech's School of Chemical and Biomolecular Engineering. "That means there is no natural mechanism to remove the particles from the eye. Knowing this, we can design biodegradable particles with drugs encapsulated in them that can slowly release those drugs over a period of time that we could control."
Currently, doctors typically have two choices for administering drugs to the eye: eye drops and injection with a traditional hypodermic needle into the vitreous at the center of the eye. While injections into the vitreous do reach their target, they also affect other portions of the eye where the drug may not be desirable. Eye drops, which are simple to use, often fail to reach the structures being targeted, Prausnitz said.
Henry Edelhauser, a professor of ophthalmology at Emory School of Medicine, said pharmaceutical companies are now developing new compounds to treat eye diseases. Those drugs will be most effective if they can be delivered directly to the portion of the eye that requires treatment, such as the choroid and retina that this new delivery method targets.
"With this technique, we are keeping the drug right where it needs to be for most therapies of interest in the back of the eye," he said.
Researcher Samirkumar Patel displays a prototype microneedle used to inject therapeutics into specific locations in the eye. The technology could allow doctors to target drugs to locations in the eye that are now difficult to reach. Credit: Georgia Tech Photo: Gary MeekThe microneedles used in the technique are made of stainless steel and are less than one millimeter long. The researchers believe that they will cause less trauma to the eye than the larger hypodermic needles, and reduce the risk of infection.
The model compounds used in this study fluoresced inside the eye, showing researchers that they had reached their targets. But the compounds studied were not drugs, so the next step, according to Edelhauser, will be to study how well the microneedle technique can get real drugs to the eye structures of interest.
The technology has been licensed to an Atlanta-based startup, Clearside Biomedical, which plans to advance the micro-injection technology developed in collaboration between the research groups of Mark Prausnitz at Georgia Tech and Henry Edelhauser at Emory.
Clearside Biomedical was formed with the assistance of Georgia Tech's VentureLab program, which helped obtain early-stage seed funding from the Georgia Research Alliance. Clearside has received $4 million in funding mostly from Hatteras Venture Partners, a venture capital firm based in Durham, N.C.
In addition to those already mentioned, the study involved Damian Berezovsky and Bernard McCarey from the Emory Eye Center in the Emory University School of Medicine, and Vladimir Zarnitsyn from the Georgia Tech School of Chemical and Biomolecular Engineering.
Development of the intraocular microneedle demonstrates the strength of collaboration between researchers at Emory University and Georgia Tech.
"This project leveraged the skills of both institutions and came up with a solution that we could never have developed independently," Prausnitz said. "With support from the National Institutes of Health, we have developed a solution that could give patients with eye diseases the medication they need in a more effective way."
Journal reference: Investigative Ophthalmology & Visual Science
Provided by Georgia Institute of Technology
- Startup receives $4 million to develop drug delivery targeted to the back of the eye Jan 05, 2012 | not rated yet | 0
- Painless 'microneedle' patch may take the sting out of shots Aug 19, 2009 | not rated yet | 0
- Better than a needle in the eye: New medical device offers hope and relief for patients Feb 02, 2012 | not rated yet | 0
- Cheaper eye drug proves as good as pricier one Apr 28, 2011 | not rated yet | 0
- Cheaper AMD drug could lead to serious eye issues Jun 18, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
How many joules expended for a push up?
1 hour ago Just wondering if any of you can do the calculation that well approximates the amount of joules expended by a push up.
force to keep the folding doors
1 hour ago Hello, I would like to ask you to calculate the force F, which needed to keep the folding doors in this position. I would like to know what is the...
Confusion regarding direction of kinetic friction on inclined plane.
2 hours ago *please help! * The formula for kinetic friction acting on a sliding body is μkN When the body is sliding down an inclined plane fk=μkN
8 hours ago Alright, so in Pathfinder (like Dungeons and Dragons) there's a spell that allows you to lift/move stuff within 25 ft with 5 pounds of force. A...
10 hours ago So energy can only be converted... So when you squeeze the bulb on a blood pressure cuff, you are applying kinetic energy. Then the cuff fills with...
How does momentum, inertia and drag affect the motion of an object?
13 hours ago How does momentum and inertia affect changes in speed, when considering acceleration from thrust, or from decelleration from drag? Say, for a...
- More from Physics Forums - Classical Physics
More news stories
The most common cause of failure after glaucoma surgery is scarring at the surgical site, so researchers are actively looking for ways to minimize or prevent scar formation. Previous work had suggested that vascular endothelial ...
Ophthalmology 23 hours ago | not rated yet | 0 |
New research is emphasizing the importance of regular screenings for glaucoma, a disease that deteriorates the optic nerve over time and is a leading cause of irreversible blindness worldwide. The onset of glaucoma is associated ...
Ophthalmology May 17, 2013 | not rated yet | 0 |
The University of Nottingham and Nottingham University Hospitals NHS Trust, have been working with Sony Computer Entertainment Europe (SCEE) to develop special 3-D glasses and games to help treat children ...
Ophthalmology May 08, 2013 | not rated yet | 0
The first successful cornea transplant with donor endothelial tissue preloaded by an eye bank has been performed at Massachusetts Eye and Ear in Boston, Mass. Roberto Pineda II, M.D., Director of the Refractive Surgery Service ...
Ophthalmology May 07, 2013 | 5 / 5 (1) | 0
Adding omega-3 fatty acids did not improve a combination of nutritional supplements commonly recommended for treating age-related macular degeneration (AMD), a major cause of vision loss among older Americans, ...
Ophthalmology May 06, 2013 | 3 / 5 (2) | 0 |
An increasing number of U.S. children are experiencing gastrointestinal issues that require interventions to resolve, according to research presented at Digestive Disease Week (DDW).
1 hour ago | not rated yet | 0 |
A ground-breaking advance in colonoscopy technology signals the future of colorectal care, according to research presented today at Digestive Disease Week(DDW). Additional research focuses on optimizing the minimal withdrawal ...
1 hour ago | not rated yet | 0
Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.
9 hours ago | 5 / 5 (1) | 0
For combat veterans suffering from post-traumatic stress disorder, 'fear circuitry' in the brain never rests
Chronic trauma can inflict lasting damage to brain regions associated with fear and anxiety. Previous imaging studies of people with post-traumatic stress disorder, or PTSD, have shown that these brain regions can over-or ...
10 hours ago | not rated yet | 0 |
(Medical Xpress)—What if the quality of your work depends more on your focus on the piano keys or canvas or laptop than your musical or painting or computing skills? If target users can be convinced, they ...
22 hours ago | 3.7 / 5 (3) | 0 |
The neural machinery underlying our olfactory sense continues to be an enigma for neuroscience. A recent review in Neuron seeks to expand traditional ideas about how neurons in the olfactory bulb might encode information about ...
21 hours ago | not rated yet | 0 |